Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy

Transplantation

Volumn 66, Issue 8, 1998, Pages 1047-1052

  Cacciarelli, Thomas V ^a   Green, Michael ^a   Jaffe, Ronald ^a   Mazariegos, George V ^a   Jain, Ashok ^a   Fung, John J ^a   Reyes, Jorge ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GAMMA INTERFERON; GANCICLOVIR; PREDNISONE; TACROLIMUS;

ADOLESCENT; ANTIVIRAL ACTIVITY; ARTICLE; CHILD; EPSTEIN BARR VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTION RISK; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; EPSTEIN-BARR VIRUS INFECTIONS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFANT; INTESTINES; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; POSTOPERATIVE COMPLICATIONS; PREDNISONE; REOPERATION; SPLENECTOMY; SURVIVAL ANALYSIS; TACROLIMUS; TREATMENT OUTCOME;

EID: 0032573203     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199810270-00014     Document Type: Article

References (39)

1. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestation in children. Transplantation 1988; 45: 719.
2. Swinnen LJ, Costanzo-Nordin MK, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1723.
3. Malatack J, Gartner J, Urbach A, Zitelli B. Orthotopic liver transplantation, Epstein Barr virus, cyclosporine and lymphoproliferative disease: a growing concern. J Pediatr 1991; 11: 667.
4. Sokal EM, Antunes H, Begun C, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997; 64: 1438.
5. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr Virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524.
6. Sokal EM, Caragiozoglou T, Lamy M, Reding R, Otte JB. Epstein-Barr virus serology and Epstein-Barr virus-associated lymphoproliferative disorders in pediatric liver transplant recipients. Transplantation 1993; 56: 1397.
7. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation: interplay between primary Epstein- Barr virus infection and immunosuppression. Transplantation 1996; 62: 370.
8. Hanto DW, Sakamoto K, Purtilo DT, Simmons RL, Najarian JS. The Epstein-Barr virus in the pathogenesis of postransplant lymphoproliferative disorders. Surgery 1981; 90: 204.
9. Cockfield SM, Preiksaitis J, Harvey E, et al. Is sequential use of ALG and OKT3 in renal transplant recipients associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder? Transplantation 1991; 23: 1106.
10. Nalesnick MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133: 173.
11. Green M, Kaufmann M, Wilson J, Reyes J. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 1997; 25: 1344.
12. Khanna R, Burrows SR, Moss DJ. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev 1995; 59: 387.
13. Pearson GR, Orr TW. Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein-Barr virus antigens. J Natl Cancer Inst 1976; 56: 485.
14. Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985; 152: 876.
15. Cacciarelli TV, Esquivel CO, Moore DH, et al. Factors affecting survival after orthotopic liver transplantation in infants. Transplantation 1997; 64: 242.
16. Klein G. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 1994; 77: 791.
17. Rooney CM, Rowe M, Wallace LE, Rickinson AB. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T cell surveillance. Nature 1985; 317: 629.
18. Gregory CD, Murray RJ, Edwards CF, Rickinson AB. Downregulation of cell adhesion molecules LFA-3 and ICAM-I in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med 1988; 167: 1811.
19. Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375: 685.
20. DeCampos-Lima PO, Levitsky V, Brooks J, et al. T cell responses and virus evolution: loss of HLA All-restricted CTL epitopes in Epstein-Barr virus isolates from highly A-11 positive populations by selective mutation of anchor residues. J Exp Med 1994; 179: 1297.
21. Starzl TE, Demetris AJ, Murase N, Trucco M, Thomson AW, Rao AS. The lost chord: microchimerism. Immunol Today 1996; 17: 577.
22. Schwartz RS, Andre-Schwartz J, Armstrong MYK, Beldotti L. Neoplastic sequelae of allogenic disease. I. Theoretical considerations and experimental design. Ann NY Acad Sci 1966; 129: 804.
23. Pirsch JD, Stratta RJ, Sollinger HW, et al. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med 1989; 86: 241.
24. Morgan G, Superina RA. Lymphoproliferative disease after pediatric liver transplantation. J Ped Surg 1994; 29: 1192.
25. Lin JC, Smith MC, Pagano JS. Prolonged inhibitory effect of (1,3-dihydroxy-2-propoxymethyl) guanine against replication of Epstein-Barr virus. J Virol 1984; 50: 50.
26. Hanto DW, Frizzera G, Gail-Peczalska KJ, Simmons RL. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39: 461.
27. Thorley-Lawson DA, Miyashita EM, Khan G. Epstein-Barr virus and the B cell: that's all it takes. Trends Microbiol 1996; 4: 204.
28. Shapiro RS, Chavenet A, McGuire W, Pearson A, Craft A, McGlave P. Treatment of B-cell lymphoproliferative disorder with interferon alpha intravenous gamma globulin. N Engl J Med 1988; 318: 1334.
29. Taguchi Y, Purtilo DT, Okano M. The effect of intravenous j immunoglobulin and interferon-a on Epstein-Barr virus-induced lymphoproliferative disorder in a liver transplant recipient. Transplantation 1994; 57: 1813.
30. Moore KW, Vieira P, Fiorentino DF, et al. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein- Barr virus gene BCRF1. Science 1990; 248: 1230.
31. Hsu DH, Malefyt RDW, Fiorentino DF, et al. Expression of interleukin 10 activity by Epstein-Barr virus protein BCRF1. Science 1990; 250: 830.
32. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86: 3333.
33. Chen JM, Barr ML, Chadburn A, et al. Management of lymphoproliferative disorders after cardiac transplantation. Ann Thorac Surg 1993; 56: 527.
34. Langnas AN, Markin RS, Inagaki M, et al. Epstein-Barr virus hepatitis after liver transplantation. Am J Gastroenterol 1994; 89: 1066.
35. Alshak NS, Jiminez AM, Gedebou M, et al. Epstein-Barr virus infection in liver transplantation patients: correlation of histopathology and semiquantitative Epstein- Barr virus-DNA recovery using polymerase chain reaction. Human Pathol 1993; 24: 1306.
36. Howard TK, Klintmalm GB, Stone MJ, et al. Lymphoproliferative disorder masquerading as rejection in liver transplant recipients: an early aggressive tumor with atypical presentation. Transplantation 1992; 53: 1145.
37. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems: the differential activation of TH2-like effector cells in peripheral tolerance. Transplantation 1992; 53: 1281.
38. Reyes J, Zeevi A, Ramos H, et al. Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant Proc 1993; 25: 3315.
39. Rowe DT, Qu L, Reyes J, et al. Use of quantitative PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 1997; 35: 1612.